Literature DB >> 3034295

Inclusion body myositis presenting as treatment-resistant polymyositis.

L H Calabrese, H Mitsumoto, S M Chou.   

Abstract

Inclusion body myositis (IBM) has been viewed as a distinct and rare form of inflammatory myopathy. Previously reported findings from series of IBM patients have suggested that clinical and pathologic features are present which readily distinguish it from idiopathic polymyositis. We report 4 cases of IBM presenting clinically and pathologically as polymyositis, each of which was refractory to therapy. Our data suggest that IBM may be a more common and heterogeneous form of inflammatory myopathy than has been previously suggested. Furthermore, IBM may be clinically and electrophysiologically indistinguishable from polymyositis. Reasons for failing to recognize IBM by pathologic studies appear to include: the skip lesion nature of the pathologic findings, failure to examine tissues by electron microscopy, and a low level of suspicion or lack of recognition. Because of its insidious clinical course and its failure to respond to immunosuppressive therapy, IBM may be an important variant of treatment-resistant polymyositis.

Entities:  

Mesh:

Year:  1987        PMID: 3034295     DOI: 10.1002/art.1780300406

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 2.  Polymyositis/dermatomyositis: the current position.

Authors:  A Urbano-Márquez; J Casademont; J M Grau
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

3.  Preliminary observations on the role of magnetic resonance imaging for polymyositis and dermatomyositis.

Authors:  L D Kaufman; B L Gruber; D P Gerstman; A T Kaell
Journal:  Ann Rheum Dis       Date:  1987-08       Impact factor: 19.103

4.  [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].

Authors:  S Kim; E Genth; T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

5.  Inclusion body myositis with abundant ring fibers.

Authors:  M R Del Bigio; V Jay
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

6.  Inclusion body myositis: an underdiagnosed condition?

Authors:  N D Hopkinson; C Hunt; R J Powell; J Lowe
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

7.  Inclusion body myositis: clinical and histopathological features of 36 patients.

Authors:  S Beyenburg; S Zierz; F Jerusalem
Journal:  Clin Investig       Date:  1993-05

8.  Dysphagia in inclusion body myositis.

Authors:  A R Wintzen; G T Bots; H M de Bakker; J H Hulshof; G W Padberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

Review 9.  Evaluation and construction of diagnostic criteria for inclusion body myositis.

Authors:  Thomas E Lloyd; Andrew L Mammen; Anthony A Amato; Michael D Weiss; Merrilee Needham; Steven A Greenberg
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

10.  BACE-1, PS-1 and sAPPβ Levels Are Increased in Plasma from Sporadic Inclusion Body Myositis Patients: Surrogate Biomarkers among Inflammatory Myopathies.

Authors:  Marc Catalán-García; Glòria Garrabou; Constanza Morén; Mariona Guitart-Mampel; Ingrid Gonzalez-Casacuberta; Adriana Hernando; Jose Miquel Gallego-Escuredo; Dèlia Yubero; Francesc Villarroya; Raquel Montero; Albert Selva O-Callaghan; Francesc Cardellach; Josep Maria Grau
Journal:  Mol Med       Date:  2015-11-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.